In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.
Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session.
Three Motley Fool contributors were asked to identify great growth stocks down 20% or more to buy now. Here's why they chose Beam Therapeutics (NASDAQ: BEAM), Maravai LifeSciences (NASDAQ: MRVI), and Novavax (NASDAQ: NVAX). Keith Speights (Beam Therapeutics): Beam Therapeutics was flying high in the early part of 2021.
If you want solid healthcare stocks that will be worth buying and holding for the next 10 years, you need to set the bar pretty high. But thanks to its portfolio and late-stage pipeline therapies, its next few years should feature strong growth.
As far as life goals go, defeating cancer might be deemed one of the more fanciful.
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronavirus variants are circulating for an annual immunization program each fall season in the United States. The company suggested that the U.S. Food and Drug Administration select the prevalent variant of coronavirus in the first quarter each year, similar to the model employed to choose the composition for annual flu shots. The FDA in documents released on Monday proposed June for deciding on an annual COVID shot's make-up.
The drug is currently being tested as a front-line treatment
Is Merck stock a buy or a sell after Keytruda succeeded in one study but failed in another in late January? Is MRK stock a buy or a sell?
Cutting hours is meant to help ease workload for employees and better serve customers, say pharmacy chains.
The FDA could be just months away from approving Eli Lilly and Boehringer Ingelheim's drug candidate to treat a common condition.
Following a daylong meeting of an expert advisory committee to the U.S. Food and Drug Administration, all Covid-19 vaccines and boosters will soon be made to address the most current strains.
Because new medicines come with patent protection for lengthy periods of time, the pharmaceutical industry is unsurprisingly a very lucrative one. Few companies do these two things better than Merck (NYSE: MRK). Earlier this month the pharmaceutical giant closed its $1.35 billion, all-cash deal with the oncology company Imago BioSciences.
Most Walmart pharmacies will close at 7 p.m. local time instead of at 9 p.m. to help employees achieve a better "work-life" balance.
People across social media have documented changes to their faces after using Ozempic.
WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.
By Faith Ashmore, Benzinga
FDA says CBD and other cannabis-derived products require oversight that it can not currently provide given potential safety risks.
(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually. The agency is trying to simplify its COVID-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus. Vaccine makers Pfizer Inc with partner BioNTech SE and Moderna Inc introduced late last year updated versions of their COVID vaccines tailored to target Omicron variants as well as the original coronavirus.
Advisers to the Food and Drug Administration on Thursday unanimously endorsed retiring the original coronavirus shot in favor of one that targets both the original strain of the coronavirus and the omicron variant. The recommendation, if adopted by the FDA, will have minimal impact on most people, affecting unvaccinated people who have not yet received any doses of the vaccine; they were still being offered two initial shots of a vaccine based on the original form of the virus. The bivalent shot